This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This single-site study (K23) will test the hypothesis that current treatment of HIV-1 infected persons with the use of highly active anti-retroviral therapy (HAART) will place these patients at higher risk for developing atherosclerosis, as mediated through metabolic complications of these agents.
Specific Aim #1 : To characterize the effect of HAART on endothelial dysfunction in a HIV-1 population.
Specific Aim #2 : To determine whether periodontal pathogen burden (PPB) affects the rate of progression of endothelial dysfunction (ED).
Specific Aim #3 : To determine the relation between PPB and levels of systemic inflammation (as measured by high-sensitivity C-reactive protein (hs-CRP)) and progression of atherosclerosis (by measuring ED using brachial artery resistance test (BART)). The study will enroll 155 HIV-1 infected persons starting HAART and evaluate changes in ED using BART to determine whether ED is affected by PPB. Systemic inflammation, as measured by hs-CRP, will be evaluated as a mediator between PPB and ED. Atherosclerosis will be measured using the intimal medial thickness (IMT) from carotid ultrasound. Each subject will participate in four study visits over 2 years; of which, two visits will take place at the GCRC for the BART, BIA measurements, and nutrition questionnaires.
Showing the most recent 10 out of 753 publications
